Lilly’s targeted RET drug shrinks tumours in lung cancer trial EP News Bureau Sep 16, 2019 Lilly’s drug, now called selpercatinib, is intended for patients with rare RET abnormalities, which occur in about 2 per cent of…
China expands drug bulk-buy programme, puts pressure on pharma firms Reuters Sep 3, 2019 The programme, rolled out last year, saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process…
